Sophia Randolph, M.D., Ph.D., is Chief Medical Officer. As a medical oncologist, Dr. Randolph brings over 20 years of experience in oncology drug development advancing novel therapeutics from preclinical through late-stage settings. Prior to joining Kivu Bioscience, Dr. Randolph served as Chief Medical Officer at ALX Oncology, where she built and led a cross functional clinical development organization progressing novel biologic therapies targeting the CD47/SIRPalpha checkpoint pathway. Prior to ALX, she was with Pfizer Oncology and with increasing roles and responsibilities, advanced the clinical and translational development of multiple small molecule therapeutics including Xalkori® (crizotinib) and Ogsiveo® (nirogacestat) through early development. As Executive Director at Pfizer, she served as the global clinical franchise lead for Ibrance® (palbociclib), leading the clinical development team from first-in-human trials through global regulatory approval. 

Previously, Dr. Randolph was at Merck, where she served as clinical development lead and molecular profiling lead across multiple early development oncology programs including Zolinza® (vorinostat). Dr. Randolph holds an A.B. in Biochemistry from Harvard University and both an M.D. and Ph.D. in Cellular and Molecular Biology from the University of Michigan. She completed her oncology fellowship training at the University of Washington/Fred Hutchinson Cancer Research Center.